Pay-for-delay settlements remain steady in EU

The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Teva responds ‘robustly’ to EU pay-for-delay charge

15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

Americas

Pay-for-delay settlements fall for second year: FTC report

6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.

More on this story

Europe

Teva responds ‘robustly’ to EU pay-for-delay charge

15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

Americas

Pay-for-delay settlements fall for second year: FTC report

More on this story

Europe

Teva responds ‘robustly’ to EU pay-for-delay charge

15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

Americas

Pay-for-delay settlements fall for second year: FTC report